RESUMEN
OBJECTIVES: In this study, it was aimed to investigate whether or not plateletrich plasma (PRP) causes intra-abdominal adhesions and therefore, whether or not PRP can be used safely in intra-abdominal operations. METHODS: Of the total of 35 animals, 5 were used as donors for the preparation of plateletrich plasma (PRP). The surgical procedures were performed on the remaining 30 animals. These rats were randomized and divided into 3 groups of 10. In Group 1, no adhesion induction was performed. Adhesion was induced by cecal abrasion and peritoneal resection model in Groups II and IIII. In Group 2, no treatment was given. In Group 3, 1 cc PRP was applied on the cecum. The rats were sacrificed on postoperative day 21. RESULTS: According to adhesion scores, the difference between the sham and PRP groups was not statistically significant. There was also no significant difference between the control and PRP groups, but the adhesion scores in the PRP group was lower than those in the control group. On histopathological evaluation, the difference between the sham and PRP groups was not statistically significant. There was also no significant difference between the control and PRP groups, but the average fibrosis and inflammation scores in the PRP group were lower than those in the control group. CONCLUSION: The results of the present study have demonstrated that PRP neither reduced nor exacerbated postoperative adhesions. Thus, PRP can be used safely in experimental and clinical studies where it will be applied intra-abdominally (Tab. 2, Fig. 3, Ref. 11).
Asunto(s)
Abdomen/cirugía , Plasma Rico en Plaquetas , Complicaciones Posoperatorias/etiología , Adherencias Tisulares/etiología , Cavidad Abdominal/patología , Cavidad Abdominal/cirugía , Animales , Ciego , Femenino , Masculino , Peritoneo/patología , Peritoneo/cirugía , Complicaciones Posoperatorias/patología , Ratas , Ratas Wistar , Factores de Riesgo , Adherencias Tisulares/patologíaRESUMEN
BACKGROUND: Eugenol an essential oil found in clove was previously shown to have some anti-inflammatory properties. It also was shown to be linked to hepatoprotective effect. In this regard, we aimed to reveal the effect of eugenol on cholestatic liver disease. METHOD: Cholestatic liver disease model was established in 20 rats via bile duct ligation. Eugenol was administered and cytokine levels and liver histology after sacrifice were evaluated. RESULTS: Biliary ductular proliferation and neutropil infiltration were lower in eugenol-administered rats. CONCLUSION: Eugenol has a promising effect on liver histology in cholestatic liver disease (Tab. 1, Fig. 2, Ref. 16).
